接种BNT162b2、CoronaVac和ChAdOx1疫苗及SARS-CoV-2感染后主要不良心脑血管事件风险:自我对照病例系列研究
该自我对照病例系列研究利用马来西亚全国健康数据库,纳入2021年2月24日至2022年6月30日住院的≥18岁人群,评估接种BNT162b2、CoronaVac和ChAdOx1疫苗及SARS-CoV-2感染后21天内主要不良心脑血管事件(MACCE)风险。结果显示,三种疫苗各剂次接种后MACCE风险未升高,而SARS-CoV-2感染显著增加MACCE风险。
要点
- 接种BNT162b2、CoronaVac和ChAdOx1疫苗后21天内MACCE风险未升高。
- SARS-CoV-2感染显著增加无心血管病者(IRR 3.54)和有心血管病者(IRR 1.98)的MACCE风险。
- 作者认为这些COVID-19疫苗安全性良好,总体获益-风险比仍为正向。
核心结论
- 研究结果支持这些COVID-19疫苗具有良好的安全性特征,并表明COVID-19疫苗的总体获益-风险比仍为正向。
研究设计与样本
- 自我对照病例系列研究,使用马来西亚全国健康数据库。
- 纳入2021年2月24日至2022年6月30日期间住院的≥18岁个体。
- 暴露为COVID-19疫苗接种和SARS-CoV-2感染,风险期为暴露后第1天至第21天。
- 采用条件泊松回归模型估计发病率和发病率比(IRR)及95%置信区间(CI)。
主要发现
- 接种后21天内MACCE风险(每10万剂)分别为:BNT162b2 12.0(95% CI 11.9-12.1)、CoronaVac 9.2(95% CI 9.1-9.3)、ChAdOx1 6.8(95% CI 6.6-7.0)。
- 对于无既往心血管疾病(CVD)的个体,BNT162b2、CoronaVac和ChAdOx1疫苗第一、第二或第三剂接种均未显示MACCE风险增加,有CVD的个体结果一致。
- 同源或异源加强接种方案均未显示MACCE风险增加。
- 在无CVD的印度裔人群中,ChAdOx1第一剂接种后MACCE风险轻度升高(IRR 1.64;95% CI 1.08-2.48),其他亚组分析未观察到显著关联。
- SARS-CoV-2感染与无CVD个体(IRR 3.54;95% CI 3.32-3.76)和有CVD个体(IRR 1.98;95% CI 1.61-2.34)的MACCE风险显著增加相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the potential risk of major adverse cerebro-cardiovascular events (MACCE) associated with COVID-19 vaccination and SARS-CoV-2 infection. METHODS: This self-controlled case series study used nationwide health database from Malaysia. The study included individuals aged ≥18 years who were hospitalised between 24 February 2021 and 30 June 2022. Outcomes were composite of MACCE: stroke, acute ischaemic heart disease, and cardiovascular death. Exposures were COVID-19 vaccination and SARS-CoV-2 infection. The risk period was day 1 to day 21 following exposure. Conditional Poisson regression model was used to estimate the incidence rate ratios (IRRs) and 95 % confidence interval (CI) comparing the outcomes in the risk and control periods. RESULTS: The risk of MACCE within 21 days after vaccination per 100,000 doses administered were 12.0 (95% CI 11.9-12.1) (BNT162b2), 9.2 (95% CI 9.1-9.3) (CoronaVac), and 6.8 (95% CI 6.6-7.0) (ChAdOx1). The incidence rate ratios showed no increased risk of MACCE associated with the first, second, or third doses of BNT162b2, CoronaVac, and ChAdOx1 vaccines for individuals without prior cardiovascular disease (CVD). This finding was consistent for individuals with CVD. Vaccine booster dose, whether in a homologous or heterologous schedule, did not show increased risk of MACCE. Analysis by ethnic groups detected a slightly elevated risk of MACCE in Indian after the first dose of ChAdOx1 (IRR 1.64; 95% CI 1.08-2.48) in those without CVD. No significant association were observed in other subgroup analyses. SARS-CoV-2 infection was associated with significantly increased risk of MACCE in individuals without CVD (IRR 3.54; 95% CI 3.32-3.76) and with CVD (IRR 1.98; 95% CI 1.61-2.34). CONCLUSIONS: Our findings support the favourable safety profile of these COVID-19 vaccines and indicate that the overall benefit-risk ratio of the COVID-19 vaccines remains positive.
引用
- Ab Rahman N, King TL, Peariasamy KM, et al. Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study. Vaccine. 2024. PMID: 39447251. doi:10.1016/j.vaccine.2024.126465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。